Here's Why NewLink Genetics Is Vaulting 45% Higher Today

Here's Why NewLink Genetics Is Vaulting 45% Higher Today

After updating data from its ongoing phase 2 trial of IDO-inhibitor indoximod in advanced melanoma, shares in NewLink Genetics Corporation (NASDAQ: NLNK) shares are jumping 45% at 12:15 p.m. EDT Thursday.

NewLink Genetics' IDO-inhibiting cancer drug pipeline was dealt blows earlier this summer when a mid-stage trial of indoximod in breast cancer patients failed and Roche Holdings returned the rights to GDC-0919, a second-generation IDO-inhibitor. The disappointments caused NewLink Genetics' shares to lose almost half of their value.

Image source: Getty Images.

Continue reading

Source: Fool.com